RELAPSED

作品数：95被引量：150H指数：7
导出分析报告
相关领域：医药卫生农业科学更多>>
相关作者：关涛苏丽萍马莉赵瑾王晶荣更多>>
相关机构：上海市第一人民医院绍兴文理学院绍兴市人民医院浙江省人民医院更多>>
相关期刊：《Asian Journal of Andrology》《Journal of Integrative Medicine》《Open Journal of Blood Diseases》《Cellular & Molecular Immunology》更多>>
相关基金：国家自然科学基金北京市自然科学基金广东省自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
选择条件：
  • 期刊=Blood Sciencex
共 条 记 录，以下是1-3
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Targeting HMGCS1 restores chemotherapy sensitivity in acute myeloid leukemia
《Blood Science》2024年第3期11-22,共12页Cheng Zhou Jue Li Xiaofan Sun Liang Zhao Huien Zhan Hui Liang Peng Fang Tuo Zhang Qiongzhi He Juan Du Hui Zeng 
supported by the National Natural Science Foundation of China to H.Z.(Grant Nos.81770184,81970143,and 82270167)and L.Z.(Grant No.81800174);the Talent Young Program of Guangdong Province(2021B1515020017),and the Leading Talents Program from The First Affiliated Hospital of Jinan University to H.Z.
Acute myeloid leukemia(AML)is a common hematological malignancy with overall poor prognosis.Exploring novel targets is urgent and necessary to improve the clinical outcome of relapsed and refractory(RR)AML patients.Th...
关键词：Chemotherapy sensitivity HMGCS1 MAPK pathway Relapsed and refractory AML Targeted therapy 
Ivosidenib in Chinese patients with relapsed or refractory isocitrate dehydrogenase 1 mutated acute myeloid leukemia:a registry study
《Blood Science》2024年第3期33-41,共9页Mingyuan Sun Qingsong Yin Yang Liang Chunkang Chang Jing Zheng Jian Li Chunyan Ji Huiying Qiu Junmin Li Yuping Gong Sheng Luo Yan Zhang Rumei Chen Zhenwei Shen Zenglian Yue Siyuan Wang Qingmei Shi Jason Yang Jie Jin Jianxiang Wang 
Ivosidenib,an isocitrate dehydrogenase 1(IDH1)inhibitor,has demonstrated clinical benefits in a pivotal study(AG120-C-001)in patients with IDH1-mutated(mIDH1)acute myeloid leukemia(AML).A registry study(CS3010-101:NCT...
关键词：China IDH1 mutation Ivosidenib Relapsed or refractory acute myeloid leukemia 
Pulmonary tuberculosis infection and CMV reactivation following daratumumab treatment in a patient with relapsed plasmablastic lymphoma
《Blood Science》2022年第4期205-208,共4页Wenyue Cao Yuling Wan Xingcheng Yang Wei Huang Jia Wei 
the fundings from the National Natural Science Foundation of China(81873427 and 82070217 to Dr.Jia Wei);CHEN XIAO-PING Foundation for the Development of Science and Technology of Hubei Province(CXPJJH12000009-113,to Dr.Jia Wei).
Plasmablastic lymphoma(PBL)is an aggressive lymphoma with limited treatment strategies.Tuberculosis(TB)infection poses a high risk for patients with hematologic malignancies,especially those treated with immune agents...
关键词：CMV Daratumumab Plasmablastic lymphoma TUBERCULOSIS 
全选清除导出
共1页<1>
检索报告 对象比较 聚类工具 使用帮助 返回顶部